<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="484">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377620</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 18424-369</org_study_id>
    <nct_id>NCT04377620</nct_id>
  </id_info>
  <brief_title>Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the
      treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS)
      who require mechanical ventilation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2020</start_date>
  <completion_date type="Anticipated">September 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who have died due to any cause</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>To evaluate the 28-day mortality rate of ruxolitinib 5 mg BID + SoC therapy and ruxolitinib 15 mg BID + SoC compared with placebo + SoC therapy, in participants with COVID-19-associated ARDS who require mechanical ventilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilator free days</measure>
    <time_frame>Day 29</time_frame>
    <description>Number of days participant did not require mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU free days</measure>
    <time_frame>Day 29</time_frame>
    <description>Number of days participant is out of the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen free days</measure>
    <time_frame>Day 29</time_frame>
    <description>Number of days participant did not receive supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor free days</measure>
    <time_frame>Day 29</time_frame>
    <description>Number of days without use of vasopressor therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital free days</measure>
    <time_frame>Day 29</time_frame>
    <description>Number of days Partcipant is out of the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the COVID-19 ordinal scale</measure>
    <time_frame>Day 15 and 29</time_frame>
    <description>Clinical status of participant at Day 15 and 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SOFA Score</measure>
    <time_frame>from baseline to Days 3, 5, 8, 11, 15, and 29</time_frame>
    <description>SOFA score is a scoring system to determine the extent of a person's organ function or rate of failure. The score is based on 6 different scores, 1 each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-related adverse events</measure>
    <time_frame>Day 29</time_frame>
    <description>Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Placebo + Standard of Care (SoC)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ruxolitinib 5mg + Standard of Care (SoC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib 5mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ruxolitininb 15mg + Standard of Care (SoC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib 15mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered BID approximately 12 hours apart</description>
    <arm_group_label>Placebo + Standard of Care (SoC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinb administered BID approximately 12 hours apart</description>
    <arm_group_label>Ruxolitinib 5mg + Standard of Care (SoC)</arm_group_label>
    <arm_group_label>Ruxolitininb 15mg + Standard of Care (SoC)</arm_group_label>
    <other_name>INCB018424</other_name>
    <other_name>Oral Jak Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant or guardian health proxy must provide informed consent before any study
             assessment is performed.

          -  Male or female participants aged ≥ 12 years.

          -  Participants with coronavirus (SARS-CoV-2) infection confirmed ≤ 3 weeks prior to
             randomization by any test with local regulatory approval.

          -  Participants who are intubated and receiving mechanical ventilation due to
             COVID-19-associated ARDS and have a PaO2/FiO2 of ≤ 300 mmHg within 6 -hours of
             randomization.

        Participants with lung imaging showing bilateral or diffuse pulmonary infiltrates on chest
        x-ray or CT scan.

        Exclusion Criteria:

          -  Known history of hypersensitivity to any drugs or metabolites of similar chemical
             classes as ruxolitinib.

          -  Presence of severely impaired renal function defined by estimated creatinine clearance
             &lt; 15 mL/min measured or calculated by Cockcroft-Gault equation or calculated by the
             updated bedside Schwartz equation. Participants must not be receiving CRRT or
             intermittent hemodialysis at screening.

          -  In the opinion of the investigator, unlikely to survive for &gt; 24 hours from
             randomization.

          -  Suspected active uncontrolled bacterial, fungal, viral, or other infection (besides
             COVID-19).

          -  Currently receiving ECMO.

          -  Participant may not be sharing a ventilator, or co-ventilating, with any other
             patient.

          -  Treatment with anti-IL-6, IL-6R, IL-1RA, IL-1β, or GM-CSF antagonists, or a BTK
             inhibitor, within 7 days of randomization.

          -  Treatment with a JAK inhibitor within 30 days of randomization.

          -  Participants who are on long-term use of antirejection or immunomodulatory drugs.

          -  Pregnant or nursing (lactating) women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Inc.</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMass MMC - University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jefferson Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytokine storm</keyword>
  <keyword>COVID-19</keyword>
  <keyword>ARDS</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>ruxolitinib</keyword>
  <keyword>pneumonia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Janus Kinase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

